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Gestational trophoblastic neoplasia after miscarriage with dilatation  
and curettage with normal histological findings
Ciążowa neoplazja trofoblastu w następstwie poronienia u pacjentki z prawidłowymi wynikami 
badania histopatologicznego po zabiegu łyżeczkowania jamy macicy
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Gestational trophoblastic neoplasia may develop after a molar, term, ectopic pregnancy, or an abortion. The diagnosis of 
gestational trophoblastic neoplasia can be made solely based on changes in human chorionic gonadotropin levels without 
pathologic confirmation. It is important to distinguish molar pregnancy from that disease, as treatment for these entities 
differs. However, gestational trophoblastic neoplasia developing after a term or ectopic pregnancy, or an abortion may be 
difficult to diagnose, because there is no tissue confirmation. In such cases, the time between a previous pregnancy event and 
the current event, and an inconsistency between very high levels of human chorionic gonadotropin and the size of lesions in 
the uterine cavity may be warning signs of gestational trophoblastic neoplasia. The role of curettage in the treatment of the 
disease is limited. We present a case of gestational trophoblastic neoplasia that developed after an abortion, serving as 
a reminder illustration that gestational trophoblastic neoplasia can develop not only after molar pregnancies, but also after 
other pregnancy events.
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Ciążowa neoplazja trofoblastu może rozwinąć się jako powikłanie zaśniadu groniastego, ciąży donoszonej, pozamacicznej, 
zakończonej zarówno poronieniem, jak i w wyniku zabiegu. Rozpoznanie możliwe jest w oparciu o sam poziom ludzkiej 
gonadotropiny kosmówkowej, bez konieczności potwierdzenia histopatologicznego. Istotne jest rozróżnienie tej jednostki 
chorobowej od zaśniadu groniastego, jako że sposoby leczenia obu chorób różnią się. Niemniej jednak ciążowa neoplazja 
trofoblastyczna rozwijająca się w następstwie ciąży donoszonej, pozamacicznej lub zakończonej poronieniem bądź zabiegiem 
przerwania ciąży może być trudna do rozpoznania z powodu braku potwierdzenia w postaci materiału tkankowego. W takich 
przypadkach wykładnikiem objawów chorobowych może być czas od ostatniej ciąży do obecnego stanu ciążowego 
w połączeniu z nieadekwatnie wysokim stężeniem ludzkiej gonadotropiny kosmówkowej oraz wielkością zmian obecnych 
w macicy. Zabieg łyżeczkowania jamy macicy odgrywa ograniczoną rolę w leczeniu ciążowej neoplazji trofoblastycznej. 
W niniejszej pracy przedstawiamy przypadek ciążowej neoplazji trofoblastu, która rozwinęła się po przebytym poronieniu, 
w celu przypomnienia, iż choroba ta może wystąpić jako powikłanie każdej ciąży, nie tylko zaśniadowej.
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hospitalized for evaluation, as her HCG level was measured 
at 128,935 mIU/mL. Her HCG rose to 189,423 mIU/mL 
during the 4-day evaluation period in our hospital. The pel-
vic examination, chest X-ray and abdominal ultrasound 
were all normal. Pelvic ultrasound revealed millimetric 
anechoic cystic lesions at the anterior corpus of the uterus, 
which has no clear border with the bladder. The uterine cav-
ity was empty, and the endometrial thickness was 4 mm.
With these findings, the patient was diagnosed with non-
metastatic GTN developing after an abortion, and treatment 
was started following International Federation of Gynecol-
ogy and Obstetrics (FIGO) scoring(1). The FIGO GTN scor-
ing was as follows: previous gestational history, abortion, 
1 point, and pretreatment HCG level, 189,423 mIU/mL, 
4 points, for a total of 5 points(2). Considering this case as 
low-risk non-metastatic GTN, we recommended single-
agent chemotherapy. In our department, we apply a regi-
men of four sequential doses of methotrexate (MTX) and 
folinic acid for these patients(3). According to this proto-
col, a 50 mg MTX intramuscular injection is repeated every 
48 hours, for a total of four doses, and 15 mg folinic acid 
is given orally 30 hours after each injection of MTX every 
15 days, until HCG is within the normal range. In our case, 
HCG was normal after four treatments; we administered 
two more treatments (six treatments in total), and then the 
patient entered follow-up. We also started oral contracep-
tives with the chemotherapy.
DISCUSSION
While 50% of GTN cases develop after a molar pregnancy, 
the remaining 50% develop after a term pregnancy, abor-
tion, or ectopic pregnancy(1). As mentioned previously, it is 
easier to diagnose GTN developing after a molar pregnancy 
then GTN that develops after other pregnancy events. 
Because an HCG increase or plateau can be easily deter-
mined, therapy can be started immediately, as the patient 
INTRODUCTION
The term “gestational trophoblastic neoplasia” (GTN) is used to describe a metastatic or non-metastatic persistent disease that develops after a molar, term, 
or ectopic pregnancy. Pathologic confirmation is not nec-
essary for its diagnosis(1). However, tissue confirmation is 
always helpful in making a definitive diagnosis. Within this 
context, the diagnosis of GTN developing after a molar 
pregnancy can be made easily based solely on changes in 
human chorionic gonadotropin (HCG) levels, without 
pathologic confirmation, because there is already pathology 
from the previous molar pregnancy(1). However, in the case 
of GTN developing after a term or ectopic pregnancy, or an 
abortion, diagnosis can be difficult because there is no tissue 
confirmation, particularly in situations where anamnesis 
cannot be taken reliably. In such cases, the interval between 
the previous pregnancy event and the current event may 
be important. It can be easier to make a GTN diagnosis if 
this interval is too short to indicate a new pregnancy event, 
and the patient is sure that she used contraception properly. 
However, when the time after the previous pregnancy event 
is sufficiently long for a subsequent pregnancy to occur, and 
the patient did not use contraception, it is difficult to distin-
guish between molar pregnancy and GTN. It is important to 
distinguish between the two diseases, because the treatment 
of each is different. Another diagnostic criterion in this situ-
ation is an inconsistency between a very high level of HCG 
and the size of the lesion(s) in the uterine cavity. In a molar 
pregnancy, the cavity is full of trophoblastic lesions, and the 
appearance is typical on ultrasound, whereas in a GTN case, 
the cavity may be nearly empty.
This report, in which we present a GTN case that developed 
after an abortion, is aimed as a reminder for physicians that 
GTN may develop not only after molar pregnancies, but 
also after other pregnancy events. We also wanted to draw 
attention to the role of curettage in the treatment of GTN.
CASE
A 39-year-old (G2P1−C/S), 6-week pregnant woman was 
admitted to the hospital due to vaginal bleeding and under-
went curettage based on a diagnosis of inevitable abortion. 
The pathology revealed a missed abortion. About 1 month 
after this intervention, she was admitted to the same hos-
pital with vaginal bleeding, and was then referred to our 
hospital because of a very high level of HCG. We per-
formed curettage to control the bleeding after observ-
ing a molar pregnancy-like ultrasound image. The HCG 
level was measured at 114,735 mIU/mL during the ini-
tial evaluation performed at our hospital. The pathology of 
the curettage material was reported as “trophoblastic pro-
liferation − cannot rule out molar pregnancy.” The HCG 
level dropped to 11,833 mIU/mL at 2 weeks after curettage 
(Tab. 1). After neglecting the regular follow-up visits for 
1 month, the patient was admitted to the hospital again and 
Date HCG level (mIU/mL)
1. 15.10.2016 114,735 – curettage
2. 26.10.2016 11,833
3. 21.11.2016 128,935
4. 24.11.2016 189,423 – MTX started
5. 30.11.2016 58,436
6. 05.12.2016 3,085 – 2nd MTX
7. 16.12.2016 106
8. 22.12.2016 42 – 3rd MTX
9. 29.12.2016 16
10. 05.01.2017 7.5 – 4th MTX
Tab. 1. Changes in HCG levels by curettage and treatment
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is already in follow-up. However, the HCG level is equally 
important in GTN cases developing after other pregnancy 
events, and HCG changes after an ectopic pregnancy or an 
abortion should be monitored for the possibility of GTN(4). 
A very high level of HCG, lack of evidence of pregnancy 
in the uterine cavity or pelvis, and the history of abortion 
1 month earlier helped us to make the GTN diagnosis in 
this case. The empty uterine cavity in our patient, as well as 
an HCG level of 190,000, was an important factor in ruling 
out a molar pregnancy. We think that this high level of HCG 
may have been caused by trophoblastic cells, which invaded 
the myometrium similarly to invasive moles.
Any patient with bleeding after a past pregnancy event 
should be evaluated for GTN, because the most prevalent 
symptom of GTN, particularly when it develops after an 
abortion, is irregular vaginal bleeding(5). In our case, hos-
pital admission also occurred due to post-abortion vagi-
nal bleeding. 
Although the main treatment approach in non-metastatic 
low-risk disease is single-agent chemotherapy, curettage 
may be used in certain situations(6,7). Thus, curettage was 
performed in our case at first admittance because of bleed-
ing, but upon a continued increase in HCG during the 
follow-up period after curettage, we decided to start sin-
gle-agent chemotherapy. Curettage is rarely used in the 
treatment of GTN because of the risk of bleeding and rup-
ture or treatment failure. It is particularly recommended 
that HCG be below 1,500 or 5,000, to minimize compli-
cations if curettage is planned in the treatment of patients 
without bleeding(3,5,8). Although we performed curettage 
to control the bleeding, we think that the very high level 
of HCG may have prevented this treatment from being 
curative. A very high level of HCG can be indicative of 
a large amount of trophoblastic cells in the uterine wall, 
which may stimulate further trophoblastic proliferation(9).
In conclusion, the possibility of GTN after abortion or other 
pregnancy events should be kept in mind, and a diagnostic 
workup specific to GTN should be conducted, particularly 
in patients with irregular vaginal bleeding. Classical GTN 
protocols should be used in treatment, and curettage should 
only be performed in the presence of certain indications 
and conditions.
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